These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 11792559)

  • 1. Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis.
    Delmas PD
    Bone; 2002 Jan; 30(1):14-7. PubMed ID: 11792559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial.
    Delmas PD; Genant HK; Crans GG; Stock JL; Wong M; Siris E; Adachi JD
    Bone; 2003 Oct; 33(4):522-32. PubMed ID: 14555255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
    JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
    N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
    Wang C
    Am J Ther; 2017; 24(5):e544-e552. PubMed ID: 26938765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.
    Cummings SR; Karpf DB; Harris F; Genant HK; Ensrud K; LaCroix AZ; Black DM
    Am J Med; 2002 Mar; 112(4):281-9. PubMed ID: 11893367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of minodronic acid hydrate for the treatment of osteoporosis.
    Tanishima S; Morio Y
    Clin Interv Aging; 2013; 8():185-9. PubMed ID: 23440003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk: review of the literature.
    Iwamoto J; Sato Y; Takeda T; Matsumoto H
    Drugs Aging; 2012 Mar; 29(3):191-203. PubMed ID: 22372723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.
    Hochberg MC; Greenspan S; Wasnich RD; Miller P; Thompson DE; Ross PD
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1586-92. PubMed ID: 11932287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older.
    Seeman E; Vellas B; Benhamou C; Aquino JP; Semler J; Kaufman JM; Hoszowski K; Varela AR; Fiore C; Brixen K; Reginster JY; Boonen S
    J Bone Miner Res; 2006 Jul; 21(7):1113-20. PubMed ID: 16813532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
    Neer RM; Arnaud CD; Zanchetta JR; Prince R; Gaich GA; Reginster JY; Hodsman AB; Eriksen EF; Ish-Shalom S; Genant HK; Wang O; Mitlak BH
    N Engl J Med; 2001 May; 344(19):1434-41. PubMed ID: 11346808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New medication combines osteo-anabolic and anti-resorptive effects. Double strategy against osteoporosis].
    MMW Fortschr Med; 2004 Apr; 146(14):47. PubMed ID: 15344760
    [No Abstract]   [Full Text] [Related]  

  • 15. Update on osteoporosis treatment.
    Nogués X; Martinez-Laguna D
    Med Clin (Barc); 2018 Jun; 150(12):479-486. PubMed ID: 29179892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
    Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
    Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment of osteoporosis. Antiresorptive therapy.
    Miller PD
    Clin Lab Med; 2000 Sep; 20(3):603-22, viii. PubMed ID: 10986624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
    Adami S
    Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcitonin.
    Silverman SL
    Rheum Dis Clin North Am; 2001 Feb; 27(1):187-96. PubMed ID: 11285994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.
    Harrington JT; Ste-Marie LG; Brandi ML; Civitelli R; Fardellone P; Grauer A; Barton I; Boonen S
    Calcif Tissue Int; 2004 Feb; 74(2):129-35. PubMed ID: 14648009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.